RESEARKA

Several clinically relevant findings are supported by only a single source, precluding internal replication within the corpus. The positive synovial-fluid biomarker response to pentosan polysulfate in knee osteoarthritis (Skerrett 2026) has no corroborating trial, and its effect direction (positive) stands in tension with the null or negative contextual-other signals reported elsewhere. Likewise, the Alzheimer's-related CRP threshold analysis (Choi 2025) and the neurodegeneration biomarker effects of dulaglutide (Wilson 2026) each draw on one study; neither outcome class is represented by a second independent trial. Singleton outcomes carry elevated risk of chance findings, and the synthesis cannot assess heterogeneity or publication bias for these endpoints. Until additional trials replicate these signals, the single-trial findings should be treated as hypothesis-generating.

Citation Support

• source_1 Lyra 2026
• source_2 Ramos-Hernandez 2026
• source_3 Davidson 2025
• source_4 Alonso 2026
• source_5 Skerrett 2026